Annual Reports in Medicinal Chemistry
Series: Annual Reports in Medicinal Chemistry; 44;
- Publisher's listprice EUR 137.00
-
56 820 Ft (54 115 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 5 682 Ft off)
- Discounted price 51 139 Ft (48 704 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
56 820 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Elsevier Science
- Date of Publication 21 December 2009
- ISBN 9780123747662
- Binding Paperback
- No. of pages736 pages
- Size 228x152 mm
- Weight 1200 g
- Language English 0
Categories
Long description:
Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.
MoreTable of Contents:
1 Recent advances in the discovery of GSK-3 inhibitors and a
perspective on their utility for the treatment of Alzheimer's
disease
Robert G. Gentles, Shuanghua Hu,
and. Gene Dubowchik
2 Advances in the Development of Nitric Oxide Synthase Inhibitors
Shawn Maddaford, Subhash
Annendi, Jailall Remnauth, and
Suman Rakhit
3 Small Molecule Protein-Protein Interaction Inhibitors as
Therapeutic Agents for Neurodegenerative Diseases: Current
Progress and Future Hurdles
Simon Haydar and Warren Hirst
4 Case History: Chantix (varenicline tartrate) a Nicotinic Partial
Agonist Aid to Smoking Cessation
Jotham W. Coe, Hans Rollema and
Brian T. O'Neill
5 Case History on Tekturnaï¿1⁄2 /Rasilezï¿1⁄2 (Aliskiren), a Highly
Efficacious Direct Oral Renin Inhibitor as a New Therapy for
Hypertension
Juergen Maibaum and David Feldman
6 Advances in Vasopressin Receptor Agonists and Antagonists Thomas Ryckmans
7 The Emergence of GPR119 Agonists as Anti-diabetic Agents Robert Jones
8 Non-peptide Ligands for the Gonadotropin Receptors Nicole van Straten, Marco Timmers
9 Recent Advances in Coagulation Serine Protease Inhibitors
Mimi Quan and Joanne Smallheer
10 Advances in the Discovery of Anti-Inflammatory FMS Inhibitors Mark Player and Carl Manthey
11 Recent Advances in the Discovery of CB2 Selective Agonists Jayant Thatte, Sangdon Han, and Rob Jones
12 Advances in the Discovery of Small Molecule JAK3 Inhibitors Stephen Wrobleski
13 Recent Advances in Adenosine Receptor (AR) Ligands in
Pulmonary Diseases
Jeff Zablocki and Rao Kalla
14 Recent Progress in the Development of Small Molecule Inhibitors
of Insulin-like Growth Factor Receptor (IGF-1R) Kinase Dinesh Vyas and Mark Wittman
15 Case History: Discovery of Ixabepilone (IXEMPRA[TM]), a First-inclass
Epothilone Analogue for Treatment of Metastatic Breast Cancer
Robert M. Borzilleri and Gregory D.
16 Hedgehog Signaling Pathway Inhibitors as Cancer Therapeutics Stefan Peuker and Karen Miller-Moslin
17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-
3-Kinases (PI3Ks)
John M. Nuss, Amy Lew Tsuhako
and Neel K. Anand Exelixis
18 Anti-infective Activity of Artemisinin and its Semi-synthetic
Derivatives John G. D'Angelo
19 Recent Advances in the Inhibition of Bacterial Type II
Topoisomerases
Greg Bisacchi & Jacques Dumas
20 Progress Towards the Discovery and Development of Specifically
Targeted Inhibitors of Hepatitis C Virus
Nicholas A. Meanwell John F.
Kadow and Paul M. Scol
21 Inhibitors of Nuclear Hormone Receptor/Steroid Receptor
Coactivator Interactions
Terry Moore, John Katzenellenbogen
22 Safety Testing of Drug Metabolites Tom Thompson
23 A Path to Innovation: Gene Knockouts Model New Drug Action Brian Zambrowicz
24 Discovery of Novel Positron Emission Tomography (PET) Tracers Dennis McCarthy
25 The Use of Isotopically Labeled Compounds in Drug Discovery (Chad) Charles S. Elmore
26 Mechanism based inhibition of CYP3A4 and other cytochromes P450 Bernard Murray
27 Nonclinical Toxicogenomics in the Pharmaceutical Environment Bruce D. Car
28 To Market, To Market 2008 Shridhar Hegde and Michelle Schmidt
More
